Back to Search
Start Over
Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer.
- Source :
-
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Feb; Vol. 144, pp. 269-280. Date of Electronic Publication: 2020 Dec 26. - Publication Year :
- 2021
-
Abstract
- Introduction: Older patients with early breast cancer (EBC) derive modest survival benefit from chemotherapy but have increased toxicity risk. Data on the impact of chemotherapy for EBC on quality of life in older patients are limited, but this is a key determinant of treatment acceptance. We aimed to investigate its effect on quality of life in older patients enrolled in the Bridging the Age Gap study.<br />Materials and Methods: A prospective, multicentre, observational study of EBC patients ≥70 years old was conducted in 2013-2018 at 56 UK hospitals. Demographics, patient, tumour characteristics, treatments and adverse events were recorded. Quality of life was assessed using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires (EORTC-QLQ) C30, BR23 and ELD 15 plus the Euroqol-5D (eq-5d) over 24 months and analysed at each time point using baseline adjusted linear regression analysis and propensity score-matching.<br />Results: Three thousand and four hundred sixteen patients were enrolled in the study; 1520 patients undergoing surgery and who had high-risk EBC were included in this analysis. 376/1520 (24.7%) received chemotherapy. At 6 months, chemotherapy had a significant negative impact in several EORTC-QLQ-C30 domains, including global health score, physical, role, social functioning, cognition, fatigue, nausea/vomiting, dyspnoea, appetite loss, diarrhoea and constipation. Similar trends were documented on other scales (EORTC-QLQ-BR23, EORTC-QLQ-ELD15 and EQ-5D-5L). Its impact was no longer significant at 18-24 months in unmatched and matched cohorts.<br />Conclusions: The negative impact of chemotherapy on quality-of-life is clinically and statistically significant at 6 months but resolves by 18 months, which is crucial to inform decision-making for older patients contemplating chemotherapy.<br />Trial Registration Number Isrctn: 46099296.<br />Competing Interests: Conflict of interest statement The authors declare no conflict of interest. Professors Stephen Walters and Thompson Robinson are National Institute for Health Research (NIHR) Senior Investigators; Jenna Morgan is a NIHR Clinical Lecturer; and Kate Lifford is funded by the NIHR as part of this project. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, or the Department of Health and Social Care.<br /> (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Subjects :
- Aged
Aged, 80 and over
Breast Neoplasms drug therapy
Breast Neoplasms pathology
Carcinoma, Ductal, Breast drug therapy
Carcinoma, Ductal, Breast pathology
Carcinoma, Lobular drug therapy
Carcinoma, Lobular pathology
Female
Follow-Up Studies
Humans
Prognosis
Prospective Studies
Surveys and Questionnaires
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Breast Neoplasms psychology
Carcinoma, Ductal, Breast psychology
Carcinoma, Lobular psychology
Quality of Life
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0852
- Volume :
- 144
- Database :
- MEDLINE
- Journal :
- European journal of cancer (Oxford, England : 1990)
- Publication Type :
- Academic Journal
- Accession number :
- 33373871
- Full Text :
- https://doi.org/10.1016/j.ejca.2020.11.022